Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

British Journal of Cancer
J BonneterreB Bendahmane

Abstract

The purpose of the study was to evaluate the efficacy and safety of docetaxel plus epirubicin (ET) and of 5-fluorouracil plus epirubicin and cyclophosphamide (FEC) as first-line chemotherapy for metastatic breast cancer. A total of 142 patients (intent-to-treat (ITT)) with at least one measurable lesion were randomised to receive docetaxel 75 mg m(-2) plus epirubicin 75 mg m(-2) or 5-fluorouracil 500 mg m(-2) plus epirubicin 75 mg m(-2) and cyclophosphamide 500 mg m(-2) intravenously once every 3 weeks for up to eight cycles. Prophylactic granulocyte-colony-stimulating factor was only permitted after the first cycle, if required. Per-protocol analysis (n=132) gave an overall response rate for ET of 63.1% (95% confidence interval (CI), 50-78%) and for FEC 34.3% (95% CI, 23-47%) after a median seven and six cycles, respectively. Intent-to-treat population (n=142) gave an overall response rate for ET of 59% (95% CI, 47-70%) and for FEC 32% (95% CI, 21-43%) after a median seven and six cycles, respectively. The median response duration for ET was 8.6 months (95% CI, 7.2-9.6 months) and for FEC 7.8 months (95% CI, 6.5-10.4 months). The median time to progression (ITT) for ET was 7.8 months (95% CI, 5.8-9.6 months) and for FEC 5.9 mo...Continue Reading

References

Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A GreenbergA U Buzdar
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FossatiA Liberati
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ChanUNKNOWN 303 Study Group
Jan 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SjöströmJ Bergh
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoW C Wood
Jan 24, 2002·Breast Cancer Research and Treatment·M AiroldiV Recalenda
Jul 13, 2002·Expert Review of Anticancer Therapy·Jean-Marc A NabholtzAlessandro Riva
Dec 11, 2002·The Lancet Oncology·John CrownMartine Piccart
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Marc NabholtzUNKNOWN TAX 306 Study Group
Nov 26, 2003·International Immunopharmacology·F A Fitzpatrick, Richard Wheeler

❮ Previous
Next ❯

Citations

Nov 5, 2013·International Journal of Breast Cancer·Hamid Reza MirzaeiParastoo Hajian
Jan 1, 2006·Women's Health·Jean-Marc Nabholtz, Joseph Gligorov
Jun 11, 2015·The Cochrane Database of Systematic Reviews·Davina GhersiNicholas Wilcken
Jun 22, 2007·Anti-cancer Drugs·Laura G EstevezJesús García Mata
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaUNKNOWN Central European Cooperative Oncology Group (CECOG)
Jan 30, 2010·Cancer Metastasis Reviews·Kelly K Haagenson, Gen Sheng Wu
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Jean-Marc Nabholtz, Joseph Gligorov
Aug 23, 2005·Expert Review of Anticancer Therapy·Jean-Marc Nabholtz, Joseph Gligorov
Jul 30, 2005·British Journal of Cancer·D GhersiR J Simes
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henri RochéBernard Asselain
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz BurzykowskiPatrick Therasse
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine J Piccart-GebhartPatrick Therasse
Nov 13, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisUNKNOWN Breast Cancer Investigators of the Hellenic Oncology Research Group
Jan 22, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-U BlohmerS Kuemmel
Jan 23, 2019·Pharmaceutical Nanotechnology·Funmilola A Fisusi, Emmanuel O Akala
Sep 3, 2019·The Cochrane Database of Systematic Reviews·Melina L WillsonNicholas Wilcken
Apr 28, 2016·Expert Opinion on Drug Safety·Guido GiordanoAntonio Febbraro
Mar 22, 2014·Molecular and Clinical Oncology·Keiichi KontaniHiroyasu Yokomise
Mar 19, 2020·International Journal of Clinical Pharmacy·Gobi Hariyanayagam GunasekaranMuhammad Tahar Bin Rahman
Dec 11, 2008·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Jun 11, 2016·Molecular and Clinical Oncology·Keiichi KontaniHiroyasu Yokomise
Jul 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaH Zwierzina

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.